Ekso Bionics Holdings

Ekso Bionics entered into securities purchase agreements for about $5.9 million, equivalent to roughly 21% of its current market capitalization. The sale consists of 5,852 series B preferred shares with a $1,000 par value and warrants to acquire up to 355,960 common shares. The preferred shares are convertible into a total of 711,922 common shares at a conversion price of $8.22; warrant exercise begins no earlier than six months after closing and continues for five years. Net proceeds will be used for working capital and general corporate purposes; Ekso Bionics most recently reported negative free cash flow of $8.99 million over the last twelve months. » Plus sur de.investing.com

Ekso Bionics announced an agreement to be the exclusive U.S. distributor for MediTouch’s BalanceTutor rehabilitation system, after which the stock rose by about 20%. The system features a patented 4D-perturbation treadmill with multiple force and motion sensors and an overhead harness system for safe balance and fall-training therapy. Ekso views the technology as synergistic with its existing go-to-market strategy, which targets the same customer base. Ekso Bionics has a market capitalization of about $11.5 million. » Plus sur de.investing.com

Ekso Bionics has signed an exclusive distribution agreement with Israeli manufacturer MediTouch for the BalanceTutor rehabilitation system in the United States. The system uses a 4D perturbation treadmill and an overhead safety frame to enable safe fall- and balance-training, complementing Ekso Bionics’ existing exoskeleton solutions. The company views the device as a complement to its market strategy and expects it to extend patient reach. Most recently, Ekso reported a significant revenue decline in Q2 2025 and a negative earnings per share, yet the stock rose despite those results. » Plus sur de.investing.com